ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2016
Effect of human papillomavirus vaccination on cervical cancer screening in Alberta.
Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- The clinical effectiveness of one-dose vaccination with an HPV vaccine: A meta-analysis of 902,368 vaccinated women.PloS one · 2024Pooled it
- Pooled it
- Simple but not simpler: a systematic review of Markov models for economic evaluation of cervical cancer screening.Clinics (Sao Paulo, Brazil) · 2018Pooled it
- Identifying the key barriers, facilitators and factors associated with cervical cancer screening attendance in young women: A systematic review.Women's health (London, England)Pooled it
- Reduced age-wise disparity in estimated cervical cancer screening participation rates after applying hysterectomy correction: a population-based cross-sectional study.BMC women's health · 2026Article
- Review
- Social factors and age play a significant role in cervical cancer and advanced-stage disease among Danish women.BMC cancer · 2024Article
- A single dose of quadrivalent HPV vaccine is highly effective against HPV genotypes 16 and 18 detection in young pregnant women eight years following vaccination: an retrospective cohort study in Fiji.The Lancet regional health. Western Pacific · 2023Article
- Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18.American journal of epidemiology · 2020Article
- Cervical Intraepithelial Neoplasia Rates in British Columbia Women: A Population-Level Data Linkage Evaluation of the School-Based HPV Immunization Program.The Journal of infectious diseases · 2020Article
- Starting cervical cancer screening at 25 years of age: the time has come.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2019Article
- Non-Adherence To Childhood HPV Vaccination Is Associated With Non-Participation In Cervical Cancer ScreeningClinical epidemiology · 2019Article
- Opportunistic HPV vaccination at age 16-23 and cervical screening attendance in Sweden: a national register-based cohort study.BMJ open · 2018Article
- Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.The Lancet. Child & adolescent health · 2018Article
- Human Papillomavirus Vaccination and Pap Smear Uptake Among Young Women in the United States: Role of Provider and Patient.Journal of women's health (2002) · 2017Article
- Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention.Expert review of molecular diagnostics · 2017Review
- Effect of HPV on cervical cancer screening in Alberta.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2016Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA school-based program with quadrivalent human papillomavirus (HPV) vaccination was implemented in Alberta in 2008. We assessed the impact of this program on Pap test cytology results using databases of province-wide vaccination and cervical cancer screening.
methodsWe conducted a nested case-control study involving a cohort of women in Alberta born between 1994 and 1997 who had at least 1 Pap test between 2012 and 2015. Women with negative cytology results were controls. Women with low-grade (atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion) and high-grade (atypical squamous cells, cannot rule out a high-grade lesion; or high-grade squamous intraepithelial lesion) cervical abnormalities were cases. Exposure status was assigned according to records of HPV vaccination. Odds ratios (ORs) for abnormal cytology results by vaccination status were adjusted for neighbourhood income, laboratory service, rural versus urban residency, and age.
resultsThe total study population was 10 204. Adjusting for age, vaccinated women had a higher screening rate than unvaccinated women (13.0% v. 11.4%, p < 0.001). Among women who received full vaccination (≥ 3 doses), the adjusted OR for cervical abnormalities was 0.72 (95% confidence interval [CI] 0.63-0.82). For high-grade lesions, the adjusted OR was 0.50 (95% CI 0.30-0.85). With 2-dose HPV vaccination, the adjusted OR for cervical abnormalities was 1.08 (95% CI 0.84-1.38).
interpretationQuadrivalent HPV vaccination significantly reduced high-grade cervical abnormalities but required 3 doses. Vaccination against HPV was associated with screening uptake. Population-based vaccination and screening programs should work together to optimize cervical cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.